“Global Sickle Cell Disease Treatment Market is anticipated to surpass USD 2.5 billion by 2020”, says Visiongain

07 November 2019
Pharma

Visiongain has launched a new pharma report “Sickle Cell Disease Treatment Market Report 2020-2030” Prospects by Type (Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant), Disease type (Sickle Cell Anemia, Sickle Beta Thalassemia, Sickle Hemoglobin C Disease, Others), End use (Hospitals, Diagnostic centers, Others), and Geography.

The global sickle cell disease treatment (SCD) market is projected to grow on account potential launch of pipeline drugs over the forecast period, increased adoption of novel therapeutics, growing awareness about hematological malignancies, improved healthcare infrastructure, and growing research and development among other contributing factors. The global market is projected to grow at a lucrative CAGR of ~15% over the forecast period 2020-2030 and anticipated to surpass USD 2.5 billion by 2020.

Sickle cell disease (SCD) is a rare genetic blood disorder characterized by hemoglobin polymerization of red blood cells (RBCs) which distorts the cells into a sickle shape. The skewed RBCs contribute to several complications associated with heart attacks, acute chest syndrome, and anemia, such as vaso-occlusion (VOC). With SCD there is no curative treatment other than an allogeneic hematopoietic stem cell transplant with a compatible (most often sibling) donor.

The cornerstones of SCD treatment are prophylactic penicillin to avoid serious infections, pain episodes analgesics, hydroxyurea to enhance the production of an alternative form of hemoglobin, and blood transfusions, but a strong unmet need for enhanced therapies remains. Drug manufacturers have recognized the business prospect in SCD, developing agents with new action mechanisms that target the basic genetic defect and reduce VOC. A strong & diverse late-stage pipeline is anticipated to be a key driving factor for significant SCD market growth by 2030, although patients are awaiting potential early-stage curative options.

Over recent years, the number of cases of sickle cell disease has increased significantly. In African-Americans, the disease is more prevalent as compared to Hispanic-Americans and Asian-Americans. The prevalence of this disease is attributed to the increasing prevalence among patients with sickle cell trait. Advances in treatment methods such as bone marrow transplantation and blood transfusion, however, have significantly reduced the mortality rate for sickle cell disease patients. The highest proportion of patients with sickle cell anemia showed a decline in mortality rates.

Research on several regenerative therapies, including gene therapy performed by various drug suppliers, is in the early stages of clinical trials. Although it is not predicted that these therapies will be accepted during the forecast period, the curative quality of these therapies will popularize these therapies among patients and thus encourage new vendors to enter the market.

In contrast, the current treatment procedures are complex and unpleasant for sickle cell disorders such as blood transfusion and hematopoietic stem cells. Gene therapy will help these obstacles to be resolved. The emergence of regenerative therapy is thus established as a key development that will fuel the growth of the demand for sickle cell disease treatment market at a CAGR of over 15% over the forecast period.

It is projected that emerging markets such as Ghana, Nigeria, South Africa, Mexico, Brazil, Saudi Arabia, and India will display lucrative growth over the forecast period due to increased awareness of hematological malignancies, favorable government policies, improved health infrastructure, and increased investment.

In the year 2018, the U.S. dominated the global sickle cell disease treatment market, followed by the U.K. and France. Although France is expected to experience a CAGR of over 10%, the U.S. is expected to maintain its dominant position over the forecast period owing to factors such as the imminent release of experimental drugs, increased adoption of new treatments, the emergence of a growing African-American population, and high treatment costs.

Recently, in September 2019; Global Blood Therapeutics, Inc. announced that the United States FDA has accepted its New Drug Application (NDA) for its lead candidate voxelotor, which has been developed for the treatment of SCD. It is an oral, once-daily therapy for patients over 12 years of age. If approved, voxelotor would be the first therapy that targets hemoglobin polymerization, the key cause of sickle cell disease.

Some of the major players operating in this industry are AstraZeneca Plc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Baxter International Inc., Emmaus Life Sciences, Inc., Bluebird bio, Inc., Global Blood Therapeutics Inc., Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Arena Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Prolong Pharmaceuticals, Bellicum Pharmaceuticals, Gamida Cell, and Modus Therapeutics, among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever